Concepedia

Author

C. Logothetis

The University of Texas MD Anderson Cancer Center

Also Known As

C J Logothetis, C LOGOTHETIS, C Logothetis, C. J. LOGOTHETIS, C. J. Logothetis, C. Logothetis, C.J. Logothetis, Christapher Logothetis, Christopher J. Logothetis, Christopher Logothetis

114

Publications

4.7K

Citations

25

H-Index

67

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterSpanish Oncology Genitourinary GroupInstitut Gustave RoussyMemorial Sloan Kettering Cancer CenterBaylor College of Medicine
CL

About

C. Logothetis is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, urology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

30

3.5K

2

Health Sciences

4

4

2.2K

3

Cell Biology

4

4

155

4

Biochemistry

1

1

24

5

Diagnostic Sciences

1

1

33

C. Logothetis

×

42

Publications

4.5K

Citations

25

H-Index

YearCitations

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher,

The Lancet Oncology

2014

1.5K

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

C. Logothetis, F. H. Dexeus, Laura Finn,

Journal of Clinical Oncology

1990

616

Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases

Hisanori Uehara, Seung Jun Kim, Takashi Karashima,

JNCI Journal of the National Cancer Institute

2003

278

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

C. Logothetis, Hang Xu, J Y Ro,

JNCI Journal of the National Cancer Institute

1992

251

Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update.

C. Logothetis, Douglas E. Johnson, Clayton Chong,

Journal of Clinical Oncology

1988

164

Collecting Duct Carcinoma of the Kidney

Meletios Α. Dimopoulos, C. Logothetis, Avi B. Markowitz,

British Journal of Urology

1993

139

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Amado J. Zurita, Eric Jonasch, X Wang,

Annals of Oncology

2011

127

Chemotherapy of extragonadal germ cell tumors.

C. Logothetis, M. L. Samuels, Debra E. Selig,

Journal of Clinical Oncology

1985

126

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.

Avishay Sella, Robert G. Kilbourn, R. J. Amato,

Journal of Clinical Oncology

1994

120

Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.

Howard I. Scher, Glenn Heller, Ana M. Molina,

Journal of Clinical Oncology

2011

113

Page 1